Cargando…

CD40 Agonist Monoclonal Antibody-Mediated Hepatitis in TNF-Receptor 1 Gene Knockout Mice

Tumor necrosis factor-alpha (TNF-α) plays an important role in liver inflammation. CD40-CD40 ligand (CD40-CD40L) is a key receptor–ligand signaling pair involved in the adaptive immune response and pathogenesis of autoimmune diseases. In mice, CD40 activation leads to sickness behavior syndrome (SBS...

Descripción completa

Detalles Bibliográficos
Autores principales:	Raabe, Oksana, Birchler, Thomas, Rehrauer, Hubert, Eppler, Elisabeth
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8389574/ https://www.ncbi.nlm.nih.gov/pubmed/34440067 http://dx.doi.org/10.3390/biomedicines9080863

Ejemplares similares

The CD40 agonistic monoclonal antibody APX005M has potent immune stimulatory capabilities
por: Bjorck, Pia, et al.
Publicado: (2015)

Characterization of a Broadly Reactive Anti-CD40 Agonistic Monoclonal Antibody for Potential Use as an Adjuvant
por: Martin, Cameron, et al.
Publicado: (2017)

Agonistic CD40 Antibodies in Cancer Treatment
por: Djureinovic, Dijana, et al.
Publicado: (2021)

Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia
por: Delgado, Raquel, et al.
Publicado: (2021)

Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
por: Salomon, Ran, et al.
Publicado: (2022)

CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches
por: Argiriadi, Maria A., et al.
Publicado: (2019)

Precision Medicine in Graves’ Disease: CD40 Gene Variants Predict Clinical Response to an Anti-CD40 Monoclonal Antibody
por: Faustino, Larissa C., et al.
Publicado: (2021)

ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
por: Mangsbo, Sara M, et al.
Publicado: (2013)

Pre-clinical development of the human CD40 agonistic antibody ADC-1013
por: Norlén, Per, et al.
Publicado: (2015)

The human CD40 agonistic antibody ADC-1013 generates immune mediated anti-tumor effects in syngeneic tumor models in hCD40 transgenic mice
por: Mangsbo, Sara M, et al.
Publicado: (2014)

Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies
por: Li, Da-Ke, et al.
Publicado: (2020)

Anti-human CD40 monoclonal antibody therapy is potent without FcR crosslinking
por: Richman, Lee P, et al.
Publicado: (2014)

CD40 monoclonal antibody and OK432 synergistically promote the activation of dendritic cells in immunotherapy
por: Zhang, Juan, et al.
Publicado: (2022)

Agonistic Anti-CD40 Antibody Triggers an Acute Liver Crisis With Systemic Inflammation in Humanized Sickle Cell Disease Mice
por: Yalamanoglu, Ayla, et al.
Publicado: (2021)

Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer
por: Sandin, Linda C, et al.
Publicado: (2014)

Accelerated elimination of human cancer cells by a CD40 agonist antibody combined with a PD-1 antagonist in CD4-depleted mice
por: Ahn, Soon-Hyun, et al.
Publicado: (2019)

CD40 agonist-induced IL-12p40 potentiates hepatotoxicity
por: Bonnans, Caroline, et al.
Publicado: (2020)

Concepts for agonistic targeting of CD40 in immuno-oncology
por: Richards, David M., et al.
Publicado: (2019)

Proimmunogenic impact of MEK inhibition synergizes with agonist anti-CD40 immunostimulatory antibodies in tumor therapy
por: Baumann, Daniel, et al.
Publicado: (2020)

Chimeric antigen receptor T cells engineered to secrete CD40 agonist antibodies enhance antitumor efficacy
por: Zhang, Yajun, et al.
Publicado: (2021)

Injectable Nanoparticle‐Based Hydrogels Enable the Safe and Effective Deployment of Immunostimulatory CD40 Agonist Antibodies
por: Correa, Santiago, et al.
Publicado: (2022)

IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer
por: Wong, Jeffrey L., et al.
Publicado: (2023)

Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer
por: Liu, Hsuan‐Chen, et al.
Publicado: (2023)

IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer
por: Wong, Jeffrey L., et al.
Publicado: (2023)

Differential lumbar spinal cord responses among wild type, CD4 knockout, and CD40 knockout mice in spinal nerve L5 transection-induced neuropathic pain
por: Cao, Ling, et al.
Publicado: (2012)

EPCT-02. PBTC-051: FIRST IN PEDIATRICS PHASE 1 STUDY OF CD40 AGONISTIC MONOCLONAL ANTIBODY APX005M IN PEDIATRIC SUBJECTS WITH RECURRENT/REFRACTORY BRAIN TUMORS
por: Lindsay, Holly, et al.
Publicado: (2020)

Early Pharmacodynamic Changes Measured Using RNA Sequencing of Peripheral Blood from Patients in a Phase I Study with Mitazalimab, a Potent CD40 Agonistic Monoclonal Antibody
por: Andersson, Hampus, et al.
Publicado: (2023)

OR19-6 A Novel Anti-CD40 Monoclonal Antibody, Iscalimab, Successfully Treats Graves’ Hyperthyroidism
por: Kahaly, George, et al.
Publicado: (2019)

Tuberculosis dissemination in kidney transplant recipient treated with anti-CD40 monoclonal antibody: a case report
por: Bednarova, Kamila, et al.
Publicado: (2022)

Concurrent Ocular and Cerebral Toxoplasmosis in a Liver Transplant Patient Treated with Anti-CD40 Monoclonal Antibody
por: Van Den Noortgate, Roos, et al.
Publicado: (2023)

CD40 and IgE: synergism between anti-CD40 monoclonal antibody and interleukin 4 in the induction of IgE synthesis by highly purified human B cells
Publicado: (1990)

Agonistic Anti-CD137 Monoclonal Antibody Treatment Induces CD11b(+)Gr-1(+) Myeloid-derived Suppressor Cells
por: Lee, Jung-Mi, et al.
Publicado: (2010)

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
por: Byrne, Katelyn T., et al.
Publicado: (2021)

Monoclonal antibodies targeting CD20
por: Chang, Chien-Hsing, et al.
Publicado: (2013)

Selective enhancement of the tumour necrotic activity of TNF alpha with monoclonal antibody.
por: Rathjen, D. A., et al.
Publicado: (1992)

Humanization and Characterization of an Anti-Human TNF-α Murine Monoclonal Antibody
por: Chiu, Wei-Chun, et al.
Publicado: (2011)

Hetero-oligomerization between the TNF receptor superfamily members CD40, Fas and TRAILR2 modulate CD40 signalling
por: Smulski, Cristian R, et al.
Publicado: (2017)

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas
por: Coveler, Andrew L, et al.
Publicado: (2023)

Understanding the influence of the tumor microenvironment on macrophage responses to CD40 agonists
por: Luheshi, Nadia, et al.
Publicado: (2014)

Agonistic CD40 antibody induces immune-mediated liver damage and modulates tumor-induced myeloid suppressive cells
por: Medina-Echeverz, Jose, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_4l87p3hqg7k0soh647r1kndj1l